Key points are not available for this paper at this time.
No takes yet. Share an insight, caveat, or question.
May lower ivabradine manufacturing costs; leaves open any effect on clinical access or outcomes.
Liu et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: